Navigation Links
Long-term cancer risk follows stem cell transplant recipients

atients was 3.1 percent. When nonmelanoma skin cancer and carcinoma in situ of the cervix were excluded, incidence was 2.3 percent. That risk was 1.85 times that of the general population. The median time to diagnosis was almost 7 years after transplant. The most commonly reported second cancers were cancers of the skin (basal and squamous cell), lung, oral cavity, and colon.

Furthermore, data analysis showed that the risk more than tripled for patients who received their transplant when they were over 40 years of age. The study also identified a new risk factor: patients who received stem cells from a female donor had almost quadrupled the risk of a second solid cancer, a risk that further increased when the patient was male. "This observation has not been previously reported in the literature and the explanation for this finding is uncertain," say the authors.

"Since the risk of developing a solid neoplasm post-allogeneic transplantation continues to increase with time," suggest the authors, "extended follow-up will be needed to more fully assess the incidence and risk factors for their development."
'"/>

Source:John Wiley & Sons, Inc.


Page: 1 2

Related biology news :

1. First North American Encapsulated Islet Transplant without Long-term Immune Suppression into a Patient with Type 1 Diabetes
2. Long-term changes in experience cause neurons to sprout new long-lasting connections
3. Long-term narcotics use for back pain may be ineffective and lead to abuse
4. Long-term marijuana smoking leads to respiratory complaints
5. Viral DNA sequence a possible trigger for breast cancer
6. Enzyme, lost in most mammals, is shown to protect against UV-induced skin cancer
7. Its not all genetic: Common epigenetic problem doubles cancer risk in mice
8. Columbia research lifts major hurdle to gene therapy for cancer
9. Combination therapy boosts effectiveness of telomere-directed cancer cell death
10. Mitochondrial DNA mutations play significant role in prostate cancer
11. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
Post Your Comments:
Breaking Biology News(10 mins):Potential new heart attack biomarker uncovered 2From fruit fly wings to heart failure -- why Not(ch)? 2ESHRE announces its campus workshop: 'Artificial Insemination: An Update' 2Sunrise Reports Financial Results for Second Quarter 2009 53821 1Sunrise Reports Financial Results for Second Quarter 2009 53821 2Sunrise Reports Financial Results for Second Quarter 2009 53821 3Sunrise Reports Financial Results for Second Quarter 2009 53821 4Sunrise Reports Financial Results for Second Quarter 2009 53821 5Sunrise Reports Financial Results for Second Quarter 2009 53821 6Sunrise Reports Financial Results for Second Quarter 2009 53821 7Sunrise Reports Financial Results for Second Quarter 2009 53821 8Sunrise Reports Financial Results for Second Quarter 2009 53821 9Sunrise Reports Financial Results for Second Quarter 2009 53821 10Sunrise Reports Financial Results for Second Quarter 2009 53821 11Sunrise Reports Financial Results for Second Quarter 2009 53821 12Sunrise Reports Financial Results for Second Quarter 2009 53821 13Sunrise Reports Financial Results for Second Quarter 2009 53821 14Sunrise Reports Financial Results for Second Quarter 2009 53821 15Sunrise Reports Financial Results for Second Quarter 2009 53821 16Sunrise Reports Financial Results for Second Quarter 2009 53821 17Sunrise Reports Financial Results for Second Quarter 2009 53821 18Sunrise Reports Financial Results for Second Quarter 2009 53821 19Sunrise Reports Financial Results for Second Quarter 2009 53821 20Micromet Inc Reports Second Quarter 2009 Financial Results 53819 1Micromet Inc Reports Second Quarter 2009 Financial Results 53819 2Micromet Inc Reports Second Quarter 2009 Financial Results 53819 3Micromet Inc Reports Second Quarter 2009 Financial Results 53819 4Micromet Inc Reports Second Quarter 2009 Financial Results 53819 5Micromet Inc Reports Second Quarter 2009 Financial Results 53819 6Micromet Inc Reports Second Quarter 2009 Financial Results 53819 7Micromet Inc Reports Second Quarter 2009 Financial Results 53819 8Micromet Inc Reports Second Quarter 2009 Financial Results 53819 9Micromet Inc Reports Second Quarter 2009 Financial Results 53819 10Micromet Inc Reports Second Quarter 2009 Financial Results 53819 11Ben Shappley Joins Amedicas Leadership Team 53817 1Ben Shappley Joins Amedicas Leadership Team 53817 2
Breaking Biology Technology:Lotus Pharmaceuticals, Inc. Appoints OTC Division Head 2Lotus Pharmaceuticals, Inc. Appoints OTC Division Head 3YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 2YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 3YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 4YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 5Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner 2Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 2Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 4Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 5Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 6